PFKFB2 siRNA

PFKFB2 siRNA is a preclinical small interfering RNA (siRNA) therapeutic candidate designed to silence the expression of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2), a key glycolytic enzyme overexpressed in various cancers. Developed by researchers at the University of Texas MD Anderson Cancer Center, the siRNA is formulated within DOPC (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine) liposomes for in vivo delivery. Silencing PFKFB2 disrupts cancer cell metabolism by increasing glycolysis while decreasing the flow of intermediates into the pentose phosphate pathway, leading to a reduction in NADPH and accumulation of reactive oxygen species (ROS). This metabolic stress activates JNK and p53 pathways, inducing G1 cell cycle arrest and apoptosis. PFKFB2 siRNA has demonstrated significant tumor growth inhibition and synergistic efficacy when combined with paclitaxel in preclinical models of wild-type TP53 ovarian and breast cancers.

Other names

liposome-encapsulated PFKFB2 siRNAPFKFB2 siRNA-DOPCPFKFB-2 siRNA-DOPCPFKFB 2 siRNA-DOPCsiPFKFB2siPFKFB-2siPFKFB 2